ALK-abello (AKBLF) Q2 2026 Earnings Report

The call emphasized strong top-line and cash-generation performance driven by tablet momentum, robust pipeline progress (peanut Phase III planning, China ACARIZAX readout) and an upgraded revenue range, while also acknowledging near-term cost increases and regulatory/market-access headwinds—most notably the German rebate increase and U.K. rollout delays for neffy. Management outlined mitigation plans and maintained long-term ambitions, suggesting confidence in growth despite some regional and timing uncertainties.

ALK updated full‑year guidance, raising the lower end of revenue growth to 14–16% in local currencies (from 13–16%) and reiterating an expected EBIT margin of around 26%; management also expects gross margin to be slightly above last year. They forecast double‑digit tablet growth across regions (tablets grew ~22% in Q2 to just over DKK 1.0bn), single‑digit growth for combined SCIT/SLIT drops (SCIT+SLIT ~DKK 515m, +7%) and low‑double‑digit growth for anaphylaxis & other products (DKK 267m, +26% in Q2; anaphylaxis +30% in Europe). Key H1 metrics underpinning the guidance: revenue DKK 3.6bn (+18% LFL), gross profit DKK 2.4bn (gross margin 68% vs 66% LY), operating profit >DKK 1bn (+20%), net profit DKK 776m (vs DKK 617m), capacity costs up 22% to DKK 1.4bn, sales & marketing +25%, free cash flow DKK 889m now expected to exceed DKK 1bn, and net debt/EBITDA ≈ -0.6; timing of China/Japan shipments and the German rebate change to 15.5% (effective 1 Jan 2027; Germany ≈25% of 2025 revenue) are highlighted as key swing factors.